CRI Genetics

Science

Clinical Study #1
50% Improvement in Remission Rates, 30% Increase in Response Rates

Summary:

1,167 subjects participated in a 24-week blinded, randomized controlled trial to assess the impact of pharmacogenomic treatment response compared to the usual “Trial & Error” treatment response.

Key Results:
  • ✓By week 8, patients who took a pharmacogenomic test experienced a 50% improvement in remission rates and a 30% increase in response rates compared to “Trial & Error.”
  • ✓The positive effects of the pharmacogenomic test compared to “Trial & Error” continued to improve throughout the duration of the 24 week study.
  • ✓Finding genetically optimal treatment for patients through pharmacogenomics consistently improved symptoms, response, and remission compared to those who did not receive a genetically optimal treatment.

Clinical Study #2
70% Improvement in Patient Symptoms

Summary:

165 subjects participated in an 8-week study that compared symptoms experienced during treatment guided by pharmacogenomic testing to the usual unguided treatment.

Key Results:
  • ✓There was a significant improvement in patient symptoms throughout the 8 weeks from pharmacogenomic testing, with an overall 70% greater improvement compared to “Trial & Error.”
  • ✓Patients with pharmacogenomics-guided treatment were 2.1 times more likely to respond to medication compared to patients with unguided treatment.
  • ✓F3 times as many doctors with pharmacogenomic guidance perceived their patients as satisfied compared to doctors without pharmacogenomic guidance.

Clinical Study #3
More than Double Likelihood of Response

Summary:

49 subjects participated in a 10-week blinded, randomized controlled that compared pharmacogenomic-guided treatment to with the usual “Trial & Error” treatment.

Key Results:
  • ✓Doctors guided by pharmacogenomic treatment found higher response and remission rates when making decisions about medication change compared to doctors without pharmacogenomic guidance.
  • ✓Pharmacogenomic testing was able to accurately predict adverse reactions to medications based on patient DNA.
  • ✓Patients who received genetically optimal treatment through pharmacogenomic testing experienced a 33.1% improvement in symptoms compared to 0.8% improvement in patients who did not receive a genetically optimal treatment.

Clinical Study #4
Improvement in Symptoms Up to 4x Greater

Summary:

44 subjects participated in an 8-week study that compared pharmacogenomic treatment to unguided “Trial & Error” treatment.

Key Results:
  • ✓Patient symptoms improved faster with pharmacogenomic treatment than without.
  • ✓Patients were more likely to receive a genetically optimal treatment after pharmacogenomic testing.
  • ✓Patients who received genetically optimal treatment through pharmacogenomic testing experienced an improvement in symptoms of up to 4 times greater than patients who did not receive a genetically optimal treatment.

Clinical Study #5
Patients Save Average of $1,036 Per Year in Medication Costs

Summary:

Over the course of 1 year, pharmacy claims were compared between patients with pharmacogenomic-based treatment and a control group.

Key Results:
  • ✓Patients with pharmacogenomic-based treatment saved an average of $1,035.60 in total annual medication costs compared to patients with “Trial & Error”-based treatments.
  • ✓Patients with pharmacogenomic-based treatment had a 17% increase in medication adherence compared to adherence prior to pharmacogenomic testing.